Home › Funds › Spruce Street Capital LP › NERV

Spruce Street Capital LP position in NERV

MINERVA NEUROSCIENCES INC · Health Care

Spruce Street Capital LP reported holding 1,655,500 shares of NERV (MINERVA NEUROSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$5.5M, representing 0.88% of its reported portfolio and ranking #27 among its reported holdings. Spruce Street Capital LP has disclosed NERV holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.66M sh
Reported value held$5.55M
Portfolio Weight0.88%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Spruce Street Capital LP's NERV position evolved

Spruce Street Capital LP first disclosed a stake in NERV in Q4 2025 at 1,655,500 shares (US$6.7M). The position peaked in Q1 2026 at 1,655,500 shares, worth US$10.0M. Across 4 filings, Spruce Street Capital LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,655,500 shares valued at US$5.5M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.66M $6.66M New
Q1 2026 1.66M $9.97M Hold
Q2 2026 1.66M $9.19M Hold
Q3 2026 1.66M $5.55M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NERV and 13F data

NERV (MINERVA NEUROSCIENCES INC) is a Health Care company. 50 other funds we track also report a position in NERV — the largest reported positions include Logos Global Management LP (US$18.3M), Vivo Capital, LLC (US$14.5M), Ally Bridge Group (NY) LLC (US$12.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NERV

All NERV fund holders →

FAQ

How long has Spruce Street Capital LP held NERV?

Spruce Street Capital LP has disclosed NERV holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Spruce Street Capital LP's current position in NERV?

As of Q3 2026, Spruce Street Capital LP holds 1.66M shares of NERV (MINERVA NEUROSCIENCES INC), valued at $5.55M, representing 0.88% of its reported portfolio and ranking #27.

Has Spruce Street Capital LP been buying or selling NERV?

In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in NERV. The position peaked in Q1 2026 at 1.66M shares.

Which other funds hold NERV?

Other major institutional holders of NERV include Logos Global Management LP, Vivo Capital, LLC, Ally Bridge Group (NY) LLC, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.